Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Taylor Wimpey upbeat for current year despite profit slide

(Sharecast News) - Taylor Wimpey posted a fall in annual revenues and profits on Thursday, but said it had seen a "robust" start to the new year as demand picked up. The blue chip housebuilder completed 10,593 homes in 2024, down on the previous year's 10,848, while the average selling price fell to £356,000 from £370,000.

As a result, revenues eased 3.2% to £3.4bn, while operating profits fell 11.5% to £416.2m. Pre-tax profits were down 32.4% at £320.3m.

The housing market has been hit by a number of factors in recent years, including soaring inflation, the cost of living crisis and high interest rates, which stretched affordability for buyers.

However, with interest rates now falling back and the current government committed to planning reform, housebuilders are becoming more optimistic.

Looking to the current year, Taylor Wimpey said the start of the spring selling season had been "robust", with good levels of demand.

In the year to the week ending 23 February, the net private sales rate was 0.75 per outlet per week, up 12% year-on-year, while pricing was flat.

Jennie Daly, chief executive, said: "Affordability, while remaining a challenge for many, especially first-time buyers, is moving in the right direction.

"As a result, our total order book is up on last year, putting us in a strong position to grow housing volumes this year. We expect to deliver full-year 2025 UK completions in the range of 10,400 to 10,800 (excluding joint ventures) and for group performance to be in line with market expectations.

"We welcome the government's recent planning reforms, which are capable of delivering a real step change in planning outcomes."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.